Zimmer’s plan to buy Biomet needs EU approval
By Sille Ruubel ( April 24, 2014, 16:08 GMT | Insight) -- Zimmer Holdings’ plan to buy rival orthopedic-device maker Biomet in a deal valued at about $13.4 billion will need approval from the European Commission, the companies say. EU antitrust enforcers can be expected to examine whether the merger will distort competition for prostheses, artificial knee joints and other devices that the two companies make.Zimmer Holdings’ plan to buy rival orthopedic-device maker Biomet in a deal valued at $13.4 billion will need approval from the European Commission, the companies say....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.